Pulmatrix Files 425 for Business Combination Communication

TL;DR

**Pulmatrix just filed a 425 for a business combination, signaling big changes ahead.**

AI Summary

This 425 filing from Pulmatrix, Inc. on March 26, 2026, is a communication related to a business combination. While the filing itself doesn't detail the specifics of the combination, it indicates that Pulmatrix, a pharmaceutical preparations company, is involved in a transaction that requires this type of disclosure. This matters to investors because business combinations can significantly alter a company's financial health, strategic direction, and future stock performance, potentially leading to either growth or dilution.

Why It Matters

This filing signals that Pulmatrix is engaged in a business combination, which could lead to significant changes in the company's structure, assets, and future prospects, directly impacting shareholder value.

Risk Assessment

Risk Level: medium — Business combinations carry inherent risks related to integration, valuation, and potential dilution, making this a medium-risk event for investors.

Analyst Insight

An investor should monitor subsequent filings (like S-4s or 8-Ks) from Pulmatrix, Inc. for details about the business combination, including terms, valuation, and potential impact on existing shares, before making any investment decisions.

Key Players & Entities

• Pulmatrix, Inc. (company) — the company filing the 425 and the subject of the filing
• 0001574235 (company) — CIK for Pulmatrix, Inc.
• 0001493152-26-012819 (company) — SEC Accession No. for this filing
• March 26, 2026 (date) — filing date and acceptance date
• 945 CONCORD STREET SUITE 1217 FRAMINGHAM MA 01701 (company) — mailing and business address for Pulmatrix, Inc.
• 2834 (company) — SIC code for Pharmaceutical Preparations

FAQ

Key Financial Figures

• $19 million — lass anti-aging biotechnology company $19 million financings to advance lead clinical can
• $1 million — “Financings”), including a $1 million investment in Pulmatrix from RCM Eos PI

Filing Documents

• form425.htm (425) — 44KB
• 0001493152-26-012819.txt ( ) — 46KB

From the Filing

Filed by Pulmatrix, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Commission File No. 001-36199 Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related disease FRAMINGHAM, MA and HOUSTON, TX — March 26, 2026 — Pulmatrix , Inc. (Nasdaq: PULM) (“Pulmatrix”) and Eos SENOLYTIX, Inc. (“Eos”), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, today jointly announced a definitive merger agreement under which Pulmatrix will acquire Eos (the “Merger”). Upon completion of the Merger, the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker symbol “EOSX.” In connection with the Merger, Eos and Pulmatrix have entered into definitive agreements for concurrent private financings of $19 million in aggregate gross proceeds (the “Financings”), including a $1 million investment in Pulmatrix from RCM Eos PIPE HOLDINGS LLC, and a bridge component for Eos from RCM Eos Holdings, LLC, both managed by Rapha Capital Management , LLC. The net proceeds are expected to support advancement of Eos’s proprietary MitoXcel™ platform , including its lead clinical candidate, PTC-2105 , for sarcopenia and sarcopenic obesity. The proposed Merger has been unanimously approved by the boards of directors of both companies and is currently expected to close in mid-2026, subject to customary closing conditions, including approval by the stockholders of each company and the effectiveness of a registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission. Following the closing of the proposed Merger and payment of all placement and M&A advisory fees, the pre-Merger Pulmatrix stockholders are expected to own approximately 6% of the combined company, while pre-Merger Eos stockholders, including investors participating in the Financings and holders of shares issued in payment of placement agent and M&A advisory fees, are expected to own approximately 94%. Eos SENOLYTIX Background and Highlights The combined company will be positioned as a leader in the emerging field of gerotherapeutics — medicines that target the root biological mechanisms of aging to improve healthspan. Strong scientific evidence shows that obesity is associated with aging, and in many cases can accelerate biological aging. Therapies targeting obesity have expanded rapidly in recent years, with most focused on GLP-1 receptor agonists, which are associated with both fat and lean mass loss, gastrointestinal side effects, and a rapid “rebound” weight regain following discontinuation. Unlike GLP-1 receptor agonists that focus on weight reduction alone, Eos’s lead MitoXcel™ clinical candidate, PTC-2105 , targets underlying aging-associated mitochondrial dysfunction that in preclinical studies leads to dramatic improvements in body composition, including reductions in fat mass greater than seen with GLP-1s, increases in lean mass , and improvements in physical function without reduced food intake or rebound weight gain following discontinuation in animals approaching one year of treatment with a once-a-week SC injection either as monotherapy or in combination with GLP-1s. PTC-2105 brings a unique, proprietary alternative to GLP-1s that may provide significant improvements in healthspan when administered either as monotherapy or in combination with GLP-1s: First-in-class AI-driven geropeptide platform targeting the biology of aging. Eos's proprietary MitoXcel platform leverages AI-driven mitochondrial peptide design to improve body composition by increasing lean mass while reducing harmful abdominal/visceral fat, without directly targeting muscle or fat regulatory pathways, supporting a shift in obesity treatment, redefining healthy weight loss as the achievement of an optimal body composition rather than simply an optimal BMI. Lead clinical candidate targeting sarcopenia/sarcopenic obesity and aging-related disease. Eos's lead program, PTC-2105 , is a mitochondrial-targeted geropeptide designed to both enhance mitochondrial efficiency and selectively induce apoptotic self-elimination of senescent cells. In preclinical studies, PTC-2105 has demonstrated improvements in body composition, including increased lean muscle mass and reduced fat accumulation, along with enhanced physical performance, supporting a differentiated profile beyond traditional weight-loss approaches. Sarcopenia and sarcopenic obesity represent a large and growing unmet medical need. T

View Full Filing

View this 425 filing on SEC EDGAR